Optimal timing and clinical value of radiotherapy in advanced ALK-rearranged non-small cell lung cancer with or without baseline brain metastases: implications from pattern of failure analyses

Optimal timing and clinical value of radiotherapy in advanced ALK-rearranged non-small cell lung cancer with or without baseline brain metastases: implications from pattern of failure analyses

Abstract Background Despite development of several next-generation tyrosine kinase inhibitors (TKIs), crizotinib remains one of the first-line treatment options for advanced ALK-positive NSCLC and is widely used in situations where next-generation TKIs aren’t yet approved or economically inaccessibl...

Full description

Bibliographic Details
Main Authors: Jianjiao Ni, Guodong Li, Xi Yang, Li Chu, Jialei Wang, Yida Li, Liqing Zou, Yuan Li, Congying Xie, Zhengfei Zhu
Format: Article
Language:English
Published: BMC 2019-03-01
Series:Radiation Oncology
Subjects:
Non-small cell lung cancer
ALK
Radiotherapy
Pattern of failure
Brain metastases
Survival
Online Access:http://link.springer.com/article/10.1186/s13014-019-1240-1

Internet

http://link.springer.com/article/10.1186/s13014-019-1240-1

Similar Items